Abstract
Purpose :
To analyze ophthalmic and systemic treatments for ocular mucous membrane pemphigoid (OMMP).
Methods :
IRB approved retrospective chart review was performed on 70 patients identified by Epic SlicerDicer at Mayo Clinic in Arizona using the ICD-10 code L12.1 (ocular mucous membrane pemphigoid) on 8/30/23. Patients were excluded if they had no ocular involvement. These patients were seen by a single cornea specialist in a referral practice and treated in collaboration with the Dermatology department. Demographics, clinical exam, medication treatments were extracted.
Results :
39 patients who established Opthalmology care between 05/05/08 and 08/21/23 were included in the study with biopsy, serum, or clinical diangosis of OMMP. The mean age of diagnosis was 70, with 66% female patients. Of these patients, 5.1% were Foster Stage I, 25.6% were Stage II, 59% were Stage III, and 10.3% were Stage IV. Ophthalmic treatments included: trichiasis epilation (87%), serum tears (41%), moisture chambers (44%), and punctal cautery (15%). Dermatology implemented immune suppression treatments including: rituximab (79%), oral prednisone (56%), intravenous immunoglobulin (38.5%), mycophenolate mofetil (31%), dapsone (15%), azathioprine (10%), doxycycline (8%) and cyclophosphamide (3%). Six patients have noted progression of disease or current signs of inflammation.
Conclusions :
There is no current currative treatment for OMMP, rather agents are used to stabilize the disease course from progressing. Although biological agents have been mentioned as a new potential for OMMP treatment, there is limited data for its use outside of severe or refractory disease. At our center, rituximab and IVIG are used as first line therapy for most patients. Future studies will determine the efficacy and safety of this treatment over past conventional treatment protocols.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.